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Abstract 
Objective: Familial Mediterranan Fever is an hereditary  autoinflammatory disease that presents with 
recurrent febrile attacks and poly serositis.  Colchicine is the only known treatment in this diease.  However,  
nearly 5-10% of patients are resistant to colchicines. There are many different modalities in colchicine 
resistant patients,  biologic and immunosupressive drugs being the known ones. We studied the efficacy of 
Dapsone as an anti inflammatory drug in children with FMF who did not tolerate colchicine well.  
Methods: This is a case series study in 10 patients who had FMF on the base of Tel-Hashomer criteria and did 
not tolerate colchicine or did not respond to it well. Patients took 2mg/kg dapsone in single dose,  during 6 
months.   
Findings In four patients episodic attacks returned after 27 days,  so the drug was discontinued. One patient 
refused to continue the study; in five patients dapsone was taken in average for 8 months and 6 days, at least 
for 6 months. These five patients had no episodes of attack during the following observation.   
Conclusion: Dapsone could control episodic attacks of FMF in 50% of cases. It might be considered as an 
alternative therapy in FMF cases not responding to colchicine.  
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Introduction 
Famlial mediterranean fever (FMF) is a genetic 
disease characterized by recurrent painful attacks 
of fever and polyserositis, usually peritonitis,  
pleuritis and arthritis.  A typical attack can be 
prevented with regular daily administration of 
colchicine in the most patients[1]. However, about 
ten percent of patients do not respond to 
colchicine or are completely resistant to the 
drug[2]. There is no known alternative or adjunct 
to colchicine therapy, although non-steroidal anti-
inflammatory drugs (NSAIDs) may be of some 
benefit for synovial symptoms[3]. Therapeutic 
options for this important group of patients are 
unsatisfactory as proposed agents have only been 
studied in individual cases or in small,  
nonrandomized trials.  Nonetheless, patients 
suffering frequent or disabling attacks on a 
maximal tolerated dose of oral colchicine,  may be 
offered a therapeutic trial with 1 mg weekly 
intravenous colchicine,  in addition to the regular 
oral regime[4].  Alternatively, efficacy of TNF 
inhibitors has been shown in several case reports, 
with significant improvement in attack 
parameters for both etanercept and 
infliximab[5,6,7]. Thalidomide, an anti-inflammatory 
agent with anti-TNF properties, was also 
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efficacious in a small group of patients[8]. IFN-α 
was successful in an open label trial[9].  
     Over the years, a myriad of cytokines, 
chemokines and other inflammation-associated 
proteins have been studied in FMF patients, the 
cytokine/chemokine pattern is consistent with 
nonspecific inflammation [2]. Chemotaxis and 
apoptosis and finaly inflammasome formation has 
main role in FMF inflammation[10].  
     The mechanism of colchicine in controling FMF 
attacks is not known clearly, the most important 
effect of prophylactic doses of colchicine is to 
prevent chemotaxis of neutrophils [11].  Morever 
the anti-apoptosis effect of colchine also has been 
shown [12].  
     Dapsone has been the principal drug in a 
multidrug regimen recommended by the World 
Health Organization for the treatment of leprosy 
[13]. As an anti-infective agent, it is also used for 
treating malaria [14]  and  for Pneumocystis carinii 
pneumonia in AIDS patients [15].   
     A considerable number of other inflammatory 
diseases (ITP and vasculitis) have been shown to 
respond in varying degrees to dapsone [16-21].      
Dapsone stabilizes neutrophil lysosomes[22] 
Several studies showed that dapsone may impair 
neutrophil chemotaxis [23].  Dapsone suppressed 
integrin-mediated neutrophil adherence function. 
It also inhibited chemoattractant-induced signal 
transduction and thus suppressed neutrophil 
recruitment and local production of toxic products 
in the affected skin of neutrophilic dermatoses[24].  
From the above, can be concluded that neutrophils 
and neutrophil products are the major targets for 
this drug.  
     We observed similar therapeutic effects of 
dapsone with colchicines.  This observation led us 
to try dapsone in FMF patients who could not 
tolerate colchicine, and/or had side effects that 
encouraged them to discontinue the medication. 
Subjects and Methods  
This was a descriptive study conducted in FMF 
and periodic fever clinic in Ardabil University of 
Medical Sciences. We identified 10 children among 
FMF patients who fulfilled Tel-Hashomer 
diagnostic criteria for definite FMF.  We do not use 
routinely MEFV gene analysis in our FMF clinic,  it 
is limited to investigational and some doubtful 
cases[25,26].  None of patients had any symptoms 
suspicious of combined and/or associated disease 
with FMF,  like JIA and vasculitis.  
     They were on regular colchicine treatment.  All 
of the patients had GI discomfort and were 
intolerant to colchicine and showed some degree 
of tendency to refuse to continue drug taking.  
Including criteria were having FMF on the basis of 
Tel-Hashomer criteria, and any side effect of 
colchicine,  especially GI symptoms.  
     The patients were informed about the possible 
benefits and potential side-effects of dapsone, and 
they accepted to take the drug at least for 6 
months.    Informed consent approved by the 
ethical committee of our institute (ARUMS) was 
obtained from each patient’s parents.   
     One patient in this group disagreed to continue 
the study.   
     In all patients G6PD was checked before 
dapsone with 2mg/kg dosage was begun.  Patients 
were observed closely for the side effects of 
dapsone,  especially on GI,  liver and hematological 
aspect.  
Findings 
Four patients had recurrent episodes like before 
colchicine therapy after a few weeks (in average 
27 days) of dapsone medication, so discontinuing 
it they were excluded from the study.  One patient 
refusesd to take the drug and five patients took 
dapsone for averagely 8 months and 6 days,  at 
least for 6 months. These five patients did not 
have any episode during study.  The patients’ 
characteristics and result of treatment are 
summarized in Table 1.  
Discussion 
Chemotaxis, apoptosis and finally inflammasome 
formation has main role in FMF inflammation [10]. 
The most important effect of prophylactic doses of  
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Table 1: Characteristics of patients with Familial Mediterranean Fever and result of treatment with Dapsone 
9yr 
8yr 
7yr 
7yr 
10yr 
6yr 
7yr 
5yr 
8yr 
6yr 
Age 
7 days 
14 days 
14 days 
15 – 20 
days 
20 -30 
days 
7 days 
Variable 
At first : 30 
days Then: 
3-8days
2 days 
7-10 days 
Period of 
attack 
Before  colchicine 
8 -9 hr 
48hr 
More than 
96 hr 
3 -4 hr 
24 hr 
24 hr 
3 -12 hr 
o. 5 – 24 
hr 
1 -2 hr 
72 - 96 hr 
D
uration 
6 10 
10 
10 9 
7 - 8 
9 10 
10 
10 
Severity
 
2yr 
6yr 
4yr 
5yr 
4yr 
2yr 
2yr 
1. 5yr 
3. 5yr 
1. 5yr 
Age at onset 
of colchicine
After colchicine 
0. 5mg  BID 
0. 5mg  daily
0. 5mg  BID 
0. 5mg  daily
0. 5mg  BID 
0. 5mg  daily
0. 5mg  daily
0. 5mg  BID 
0. 5mg  BID 
0. 5mg  BID 
D
osage of 
colchicine
 
No / pain 
Fever occasionally
2 times in 
2 years 
NO 
2 – 3 / 
month 
NO 
2 times in 
4 years 
NO 
NO 
2-3 times in 
month 
2 times in 
4. 5 years 
Period of pain 
NO 
48 – 72 hr
NO 
72 hr 
NO 
12 hr 
NO 
NO 
0. 5 – 1 hr
3 -4 hr 
D
uration
NO 
5 - 6 
NO 3 
NO 
7 - 8 
NO 
NO 7 
10 
Severity
 
50mg  daily 
50mg  daily 
50mg  daily 
50mg  daily 
50mg  daily 
30 mg  daily 
50mg  daily 
25mg  daily 
50mg  daily 
30 mg  daily 
D
osage of 
dapsone
 
After dapsone
9Mo 
9Mo 
6Mo & 8 day
10 Mo 
9 Mo 
< 7 day 
14 day 
7 day 
3Mo & 17day
3Mo & 17day
Lengthy of   
dapsone 
therapy 
 
No attack* 
NO 
NO 
NO 
NO 
NO 
2times 
1time 
1time 
1time 
N
um
ber of 
attacks 
NO 
NO 
NO  
NO 
NO 
NO 
NO 
10 
10 
10 
10 
10 
10 
10 
severity
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colchicine is to prevent chemotaxis of neutrophils 
[11].  Moreover the anti-apoptosis effect of colchine 
also has been shown [12].  In this study we used 
dapsone in FMF children.  Dapsone is an old and 
famous antibacterial drug,  but it has some  anti 
inflammatory effect [22-24],  in some aspects these 
effects are similar to the colchicine effect in FMF.  
Dapsone inhibits beta2 integrin (CD11b/CD18)-
mediated adherence of human neutrophils, 
interferes with the activation or function of the G-
protein (Gi type) that initiates the signal 
transduction cascade common to chemo- tactic 
stimuli, inhibits the generation of second 
messengers essential to the activation of beta2 
integrin molecules as well as respiratory and 
secretory functions of neutrophils exposed to 
chemo attractants [24].  In five patients we did not 
see FMF attacks during at least six months (mean,  
8 months and 6 days) of observation. Certainly it 
relates to anti-inflammatory effect of dapsone, 
which, compared with colchicine efficacy of 
80%[1],  is not very high,  but having 50% 
response, and because of similar action on 
immune response, it may be useful as an 
alternative therapy in some, especially colchicine 
resistant patients.  We did not see any side effects 
of dapsone, and it has been well tolerated in 
children.  MEFV gene analysis in these patients 
may be helpful and may give more information 
about the mutations which respond to dapsone, 
although it was not the scope of our study.  
     In the review of literature we did not find a 
similar study, and to our best knowledge, this 
seems to be the first experience on dapsone 
treatment of FMF particularly in children.   
     A limitation of this study is the lack of MEFV 
gene analysis. Another limitation is the short 
duration of the study caused by lack of long-term 
availability of the drug.  
Conclusion 
It seems that dapsone might be considered as an 
alternative therapy in FMF non- responding to 
colchicine patients. 
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